The full scientific programme for the 2026 ‘From Insight to Decision’ e-symposium, which is taking place on 2 and 8 December, has been announced by CN Bio. The event will feature expert-led sessions offering practical, real-world guidance on organ-on-a-chip (OOC) use within existing R&D strategies. 

Launched in response to landmark legislative and regulatory changes accelerating a global shift towards human-relevant technologies in non-clinical research, the e-symposium has been developed to address researchers’ common questions around adoption of OOC. The programme will discuss how OOC models are developed, where the technologies add most value and how these approaches can provide mechanistic insights that support more confident pre-clinical research decision-making.

The free-to-attend event will include four distinct sessions: an OOC masterclass covering the fundamentals, plus application-specific sessions on model development, ADME/DMPK and toxicology. 

Panel discussions, in-depth presentations, peer case studies and interactive Q&A’s will be delivered by leaders in the OOC field, including:

  • Dr Rachelle Prantil-Baun and Dr Dennis McDuffie, Novo Nordisk 
  • Dr Alexa Rizzolo, Bristol Myers Squibb 
  • Dr Emma Arnesdotter, Luxembourg Institute of Science and Technology (LIST) 
  • Dr Felice Mastroleo, Belgian Nuclear Research Centre 
  • Dr Barry Jones, Pharmaron 
  • Dr Clive Roper, Roper Toxicology Consulting 
  • Dr Yassen Abbas, Dr Emily Richardson and Dr Gareth Guenigault, CN Bio 

Dr Paul Brooks, CEO of CN Bio, said the event has been created to support the next phase of the OOC journey, “bringing together the wider OOC community to share experiences, celebrate successes and discuss the challenges facing drug developers today”.